Thursday, October 15, 2026

Salesforce -43%, Adobe -49%: Enterprise AI Software Vendors Cut Guidance as Demand Compresses

Salesforce is down 43% year-to-date and Adobe has fallen 49% year-over-year as enterprise AI software vendors slash guidance. Accenture explicitly cited 'AI demand compression' as buyers pause spending pending clearer ROI evidence. Analysts expect continued multiple compression at IBM, Infosys, and Cognizant over the next one to two quarters.

LM Salvado
LM Salvado

June 25, 2026

Salesforce -43%, Adobe -49%: Enterprise AI Software Vendors Cut Guidance as Demand Compresses
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Accenture has cut guidance, explicitly citing "AI demand compression."1 The enterprise AI application layer is hitting a demand ceiling.1 The clustering of underperformance across vendors is not coincidental — it signals a structural problem at the buyer level, not individual execution failures.

Enterprise technology buyers spent 2024 and 2025 funding AI pilots. Finance teams are now demanding proof of returns before approving renewals or new projects. Without demonstrated ROI, procurement cycles are extending and software upsell motions are stalling.

Accenture's language carries weight. As the largest IT services firm by revenue, its explicit reference to "AI demand compression" in a guidance cut is a direct signal that enterprise AI project pipelines are not converting at the pace revenue models assumed.1 The consulting-to-software flywheel that underpinned AI revenue projections has slowed.

The pressure is unlikely to stay contained. IBM, Infosys, and Cognizant draw AI consulting revenue from the same enterprise buyer base.1 If Accenture is compressing, those firms face the same headwinds in coming quarters.

For equity investors, the repricing reflects a market revising one core assumption: that AI would drive immediate, durable upsell in enterprise software.

Enterprise AI budgets are not disappearing. They are being redirected — away from application-layer software where margin expansion was priced in, and toward infrastructure and foundational model spend where ROI is more tangible. Vendors unable to show measurable cost reduction or revenue lift in live deployments are the ones absorbing the cuts.

The next one to two quarters will determine whether current guidance reductions mark a reset or the opening of a longer correction cycle.1

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com